MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Certara Inc

Gesloten

SectorGezondheidszorg

11.45 0.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.17

Max

11.53

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.8M

4.7M

Verkoop

5.6M

106M

EPS

0.029

Winstmarge

4.474

Werknemers

1,487

EBITDA

-25M

609K

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+42.54% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-324M

1.8B

Vorige openingsprijs

11.01

Vorige sluitingsprijs

11.45

Nieuwssentiment

By Acuity

50%

50%

157 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Certara Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jul 2025, 15:46 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Marktinformatie

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Winsten

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Marktinformatie

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Marktinformatie

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Acquisities, Fusies, Overnames

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Marktinformatie

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Marktinformatie

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Marktinformatie

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Acquisities, Fusies, Overnames

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Acquisities, Fusies, Overnames

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Marktinformatie

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Vergelijking

Prijswijziging

Certara Inc Prognose

Koersdoel

By TipRanks

42.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.58 USD  42.54%

Hoogste 18 USD

Laagste 14 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Certara Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

3

Buy

5

Hold

0

Sell

Technische score

By Trading Central

11.27 / 12.79Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

157 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.